XML 159 R123.htm IDEA: XBRL DOCUMENT v3.24.0.1
Equity - Adjusted income from continuing operations attributable to shareholders (Detail) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Equity [Line Items]      
Profit (loss) € (463) [1] € (1,605) [2] € 3,323 [2]
Profit (loss) from discontinued operations (10) [2] 13 [2] 2,711 [1]
Profit (loss) from continuing operations (454) [1] (1,618) [2] 612 [2]
Income from continuing operations attributable to non-controlling interests [2] (2) (3) (4)
Income from continuing operations attributable to owners of parent [2] (456) (1,622) 608
Amortization of acquired intangible assets [2] 290 363 322
Impairment loss recognised in profit or loss, goodwill [2] 8 1,357 15
Restructuring and acquisition-related charges [2] 381 202 95
Other items [2] 1,358 925 1,069
Net finance expenses [2] 18 (4) (84)
Tax impact of adjusted items [2] (450) (376) (527)
Adjusted Income from continuing operations attributable to shareholders [2] 1,148 845 1,497
Respironics litigation provision [Member]      
Equity [Line Items]      
Other items [2] 575    
Respironics field-action connected to the anticipated consent decree [Member]      
Equity [Line Items]      
Other items [2] 363 250 719
Respironics field-action running remediation costs [Member]      
Equity [Line Items]      
Other items [2] 224 210 94
Quality remediation actions [Member]      
Equity [Line Items]      
Other items [2] 175 59 94
R&D project impairments [Member]      
Equity [Line Items]      
Other items [2]   134  
Portfolio realignment charges [Member]      
Equity [Line Items]      
Other items [2]   109  
Impairment of assets in S&RC [Member]      
Equity [Line Items]      
Other items [2]   39  
Provision for public investigations tender irregularities [Member]      
Equity [Line Items]      
Other items [2]   60  
Provision for a legal matter [Member]      
Equity [Line Items]      
Other items [2] 31    
Investment re-measurement loss [Member]      
Equity [Line Items]      
Other items [2] 23    
Loss on divestment of business [Member]      
Equity [Line Items]      
Other items [2]     76
Gain on divestment of business [Member]      
Equity [Line Items]      
Other items [2] (35)    
Remaining items [Member]      
Equity [Line Items]      
Other items [2] € 2 € 63 € 87
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.
[2] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.